Thrombosis News and Research

Latest Thrombosis News and Research

Personalized rectal cancer therapy shows promise

Personalized chemotherapy for rectal cancer results in high rates of pathologic response, indicate the results of a pilot study.

19 Dec 2012

US FDA approves raxibacumab for treating inhalational anthrax

The US Food and Drug Administration have approved the monoclonal antibody raxibacumab for treatment of inhalational anthrax, caused by breathing in spores of Bacillus anthracis.

19 Dec 2012

Long physical work does not greatly influence miscarriage risk

Results from a systematic review and meta-analysis suggest that fears about substantially increased miscarriage risks in women working shifts, long hours, and in jobs involving moderate-to-high physical workload may be largely unfounded.

19 Dec 2012

Arthritis, rheumatism and total joint arthroplasty: an interview with Dr Ravi and Dr Hawker

Arthritis translates to “joint inflammation.” The most common form of arthritis is osteoarthritis (OA), which affects 12-15% of North Americans over the age of 60, and will increase in prevalence as our population ages.

19 Dec 2012

Exercise clue to long QT syndrome prognosis

The size of reduction in heart rate immediately after exercise is associated with the presence of arrhythmias in patients with long QT syndrome type 1, report researchers.

18 Dec 2012

New once-daily dual bronchodilator effective in COPD

A once-daily, inhaled, fixed-dose dual bronchodilator combination has greater efficacy than twice-daily salmeterol plus fluticasone for the treatment of chronic obstructive pulmonary disease, results of the phase III ILLUMINATE trial show.

18 Dec 2012

Lymphocyte clue to multiple sclerosis drug response

Patients with rapid recovery of CD4-positive T cells after alemtuzumab treatment for multiple sclerosis are at risk for disease progression or relapse, research suggests.

18 Dec 2012

Intramural coronary arteries indicative of vascular complications

Intramural coronary arteries, especially deep-type, are positively associated with insignificant stenosis proximal to ICA, report researchers.

18 Dec 2012

Human nociception genes mapped out

Researchers have uncovered a “network map” of genes that are involved in pain perception, which they say may help identify new analgesic drugs.

17 Dec 2012

Lapatinib benefits found for HER2-positive early-stage patients

Women with early-stage, HER2-positive breast cancer who are unable to use trastuzumab may benefit from adjuvant lapatinib treatment, suggest phase III trial findings published in Lancet Oncology.

17 Dec 2012

Dantrolene shows promise for treating DMD

A muscle relaxant called dantrolene used for treating malignant hyperthermia boosts the activity of therapies currently being developed to treat the genetic disorder Duchenne muscular dystrophy (DMD), show study findings.

17 Dec 2012

Healthy behavior at middle age is critical to 'successful' aging

Observing a combination of healthy behaviors during middle age, including moderate exercise and alcohol intake, and not smoking, can significantly improve the chances of aging successfully, study findings show.

17 Dec 2012

Less is more when it comes to antibiotics for UTI in men

Research suggests that standard antibiotic prescribing for urinary tract infections in male patients may need to be reviewed, as currently recommended 7–14-day courses appear to be no more effective than shorter ones, and may increase the risk for antimicrobial resistant or Clostridium difficile infection.

17 Dec 2012

Sit–rise test may guide mortality risk stratification

Assessing how much support a middle-aged or elderly person requires to sit and rise from the floor could be an indicator of all-cause mortality risk, researchers say.

17 Dec 2012

18FDG–PET–CT improves breast cancer staging

A prospective study has shown fluorodeoxyglucose positron emission tomography/computed tomography to be a powerful tool for the detection of nodal and distant metastatic disease in patients with breast cancer.

17 Dec 2012

AcelRx announces top-line data from Sufentanil NanoTab PCA System Phase 3 trial

AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that top-line data from its previously announced open-label, active-comparator study of its lead product candidate, the Sufentanil NanoTab PCA System, will be featured in poster presentations to be held at the 66th annual New York State Society of Anesthesiologists PostGraduate Assembly meeting in New York City to be held December 14-18, 2012.

15 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012